

Amendments to the Claims


Please cancel claims 1-35, 51-58, 61-64 and 72-74. Please add new Claims 75 and 76.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1.-35. Canceled.


~~36.~~ (Original) A polymer or copolymer characterized by a repeat unit having the formula:




wherein  $Y_1$  and  $Y_2$  are independently a lower alkylene or lower alkylene glycol group, provided that  $Y_2$  is substituted with two or more alcohol groups; each  $X$ , separately or taken together, is a physiologically acceptable anion; and said polymer or copolymer is substantially free of diphenol.


~~37.~~ (Original) The polymer of Claim ~~36~~, wherein said polymer is a homopolymer.

~~38.~~ (Previously Presented) The polymer or copolymer of Claim ~~36~~ wherein the polymer or copolymer is characterized by repeat units of formula XVI or XVII:






39. 44 (Original) A pharmaceutical composition comprising a physiologically acceptable carrier or diluent and a polymer or copolymer characterized by a repeat unit having the formula:




wherein  $Y_1$  and  $Y_2$  are each independently a substituted or unsubstituted lower alkylene or lower alkylene glycol group; and each  $X^-$ , separately or taken together, is a physiologically acceptable anion.

40. 5 (Original) The pharmaceutical composition of Claim 39, wherein at least one lower alkylene or lower alkylene glycol group represented by  $Y_1$  and  $Y_2$  is substituted.

41. 6 (Original) The pharmaceutical composition of Claim 39, wherein the polymer or copolymer is characterized by repeat units of formula XVI or XVII:





42. <sup>7</sup> (Original) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a polymer or copolymer of Claim 36. <sup>1</sup>
43. <sup>8</sup> (Original) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a homopolymer of Claim 37. <sup>2</sup>
44. <sup>9</sup> (Original) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a polymer or copolymer of Claim 38. <sup>3</sup>
45. <sup>10</sup> (Original) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 39. <sup>4</sup>
46. <sup>11</sup> (Original) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 40. <sup>5</sup>
47. <sup>12</sup> (Original) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 41. <sup>6</sup>

133

48. (Original) A method of inhibiting the growth of a microorganism on a surface comprising the step of contacting said surface with an effective amount of a polymer or copolymer of Claim ~~36~~ 11

144

(Original) A method of inhibiting the growth of a microorganism on a surface comprising the step of contacting said surface with an effective amount of a homopolymer of Claim

2


155

50. (Original) A method of inhibiting the growth of a microorganism on a surface comprising the step of contacting said surface with an effective amount of a polymer or copolymer of Claim ~~38~~ 3

51.-58. Canceled.

166

(Withdrawn) A pharmaceutical composition comprising a polymer or copolymer characterized by a repeat unit having the formula:




and a pharmaceutically acceptable carrier or diluent, wherein each X, separately or taken together, is a pharmaceutically acceptable anion.

177

59. (Withdrawn) A method of treating a microbial infection in the gastrointestinal tract of a mammal comprising the step of administering to said mammal a therapeutically effective amount of a pharmaceutical composition of claim ~~58~~ 16

61.-64. Canceled.


- 18  
65. (Withdrawn) A pharmaceutical composition comprising a polymer or copolymer characterized by a repeat unit having the formula:



and a pharmaceutically acceptable carrier or diluent, wherein each  $X^-$ , separately or taken together, is a physiologically acceptable anion.


- 19  
66. (Withdrawn) A method of treating a microbial infection of the oral mucosa or gastrointestinal tract of a mammal comprising the step of administering to said mammal a therapeutically effective amount of a pharmaceutical composition of claim 65. 18

- 20  
67. (Withdrawn) A copolymer characterized by a repeat unit having the formula:



wherein each  $X^-$ , separately or taken together, is a physiologically acceptable anion.

- 21  
68. (Withdrawn) A pharmaceutical composition comprising a polymer or copolymer characterized by a repeat unit having the formula:





(XXIII),

and a pharmaceutically acceptable carrier or diluent, wherein each  $X^-$ , separately or taken together, is a physiologically acceptable anion.


22  
69. (Withdrawn) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a copolymer of claim ~~67~~ 20

23  
70. (Withdrawn) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a pharmaceutical composition of claim 68. 21

24  
71. (Withdrawn) A method of inhibiting the growth of a microorganism on a surface comprising the step of contacting said surface with an effective amount of a copolymer of claim ~~67~~ 20

72.-74. Canceled.

25  
75. (New) A pharmaceutical composition comprising a physiologically acceptable carrier or diluent and a polymer or copolymer characterized by a repeat unit having the formula:



(XV)

wherein  $Y_1$  and  $Y_2$  are each independently a lower alkylene or lower alkylene glycol group, provided that  $Y_2$  is substituted with two or more alcohol groups; and each  $X^-$ , separately or taken together, is a physiologically acceptable anion.

26. <sup>2</sup> (New) A method of treating a microbial infection in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim ~~75~~ <sup>25</sup>